Literature DB >> 28236580

HPLC and TLC methods for analysis of [18F]FDG and its metabolites from biological samples.

Johanna Rokka1, Tove J Grönroos2, Tapio Viljanen3, Olof Solin4, Merja Haaparanta-Solin2.   

Abstract

The most used positron emission tomography (PET) tracer, 2-[18F]fluoro-2-deoxy-d-glucose ([18F]FDG), is a glucose analogue that is used to measure tissue glucose consumption. Traditionally, the Sokoloff model is the basis for [18F]FDG modeling. According to this model, [18F]FDG is expected to be trapped in a cell in the form of [18F]FDG-6-phosphate ([18F]FDG-6-P). However, several studies have shown that in tissues, [18F]FDG metabolism goes beyond [18F]FDG-6-P. Our aim was to develop radioHPLC and radioTLC methods for analysis of [18F]FDG metabolites from tissue samples. The radioHPLC method uses a sensitive on-line scintillation detector to detect radioactivity, and the radioTLC method employs digital autoradiography to detect the radioactivity distribution on a TLC plate. The HPLC and TLC methods were developed using enzymatically in vitro-produced metabolites of [18F]FDG as reference standards. For this purpose, three [18F]FDG metabolites were synthesized: [18F]FDG-6-P, [18F]FD-PGL, and [18F]FDG-1,6-P2. The two methods were evaluated by analyzing the [18F]FDG metabolic profile from rodent ex vivo tissue homogenates. The HPLC method with an on-line scintillation detector had a wide linearity in a range of 5Bq-5kBq (LOD 46Bq, LOQ 139Bq) and a good resolution (Rs ≥1.9), and separated [18F]FDG and its metabolites clearly. The TLC method combined with digital autoradiography had a high sensitivity in a wide range of radioactivity (0.1Bq-2kBq, LOD 0.24Bq, LOQ 0.31Bq), and multiple samples could be analyzed simultaneously. As our test and the method validation with ex vivo samples showed, both methods are useful, and at best they complement each other in analysis of [18F]FDG and its radioactive metabolites from biological samples.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HPLC; TLC; [(18)F]FD-PGL; [(18)F]FDG; [(18)F]FDG-1,6-P2; [(18)F]FDG-6-P

Mesh:

Substances:

Year:  2017        PMID: 28236580     DOI: 10.1016/j.jchromb.2017.01.042

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  6 in total

Review 1.  Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.

Authors:  Melanie D Sweeney; Abhay P Sagare; Berislav V Zlokovic
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

2.  Magnetic Resonance Imaging Is More Sensitive Than PET for Detecting Treatment-Induced Cell Death-Dependent Changes in Glycolysis.

Authors:  Richard L Hesketh; Jiazheng Wang; Alan J Wright; David Y Lewis; Alice E Denton; Richard Grenfell; Jodi L Miller; Robert Bielik; Marcel Gehrung; Maria Fala; Susana Ros; Bangwen Xie; De-En Hu; Kevin M Brindle
Journal:  Cancer Res       Date:  2019-05-14       Impact factor: 12.701

Review 3.  Alzheimer's disease: A matter of blood-brain barrier dysfunction?

Authors:  Axel Montagne; Zhen Zhao; Berislav V Zlokovic
Journal:  J Exp Med       Date:  2017-10-23       Impact factor: 14.307

Review 4.  Hepatic Positron Emission Tomography: Applications in Metabolism, Haemodynamics and Cancer.

Authors:  Miikka-Juhani Honka; Eleni Rebelos; Simona Malaspina; Pirjo Nuutila
Journal:  Metabolites       Date:  2022-04-02

5.  Positive effects of dietary fiber from sweet potato [Ipomoea batatas (L.) Lam.] peels by different extraction methods on human fecal microbiota in vitro fermentation.

Authors:  Yan Cao; Baoming Tian; Zhiguo Zhang; Kai Yang; Ming Cai; Weiwei Hu; Yang Guo; Qile Xia; Weicheng Wu
Journal:  Front Nutr       Date:  2022-09-07

6.  Vascular dysfunction-The disregarded partner of Alzheimer's disease.

Authors:  Melanie D Sweeney; Axel Montagne; Abhay P Sagare; Daniel A Nation; Lon S Schneider; Helena C Chui; Michael G Harrington; Judy Pa; Meng Law; Danny J J Wang; Russell E Jacobs; Fergus N Doubal; Joel Ramirez; Sandra E Black; Maiken Nedergaard; Helene Benveniste; Martin Dichgans; Costantino Iadecola; Seth Love; Philip M Bath; Hugh S Markus; Rustam Al-Shahi Salman; Stuart M Allan; Terence J Quinn; Rajesh N Kalaria; David J Werring; Roxana O Carare; Rhian M Touyz; Steve C R Williams; Michael A Moskowitz; Zvonimir S Katusic; Sarah E Lutz; Orly Lazarov; Richard D Minshall; Jalees Rehman; Thomas P Davis; Cheryl L Wellington; Hector M González; Chun Yuan; Samuel N Lockhart; Timothy M Hughes; Christopher L H Chen; Perminder Sachdev; John T O'Brien; Ingmar Skoog; Leonardo Pantoni; Deborah R Gustafson; Geert Jan Biessels; Anders Wallin; Eric E Smith; Vincent Mok; Adrian Wong; Peter Passmore; Frederick Barkof; Majon Muller; Monique M B Breteler; Gustavo C Román; Edith Hamel; Sudha Seshadri; Rebecca F Gottesman; Mark A van Buchem; Zoe Arvanitakis; Julie A Schneider; Lester R Drewes; Vladimir Hachinski; Caleb E Finch; Arthur W Toga; Joanna M Wardlaw; Berislav V Zlokovic
Journal:  Alzheimers Dement       Date:  2019-01       Impact factor: 16.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.